BidaskClub downgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a hold rating to a sell rating in a research report sent to investors on Tuesday, BidAskClub reports.

Several other research firms have also issued reports on FLXN. Laidlaw set a $18.00 price objective on Flexion Therapeutics and gave the company a buy rating in a research note on Thursday, April 11th. Benchmark restated a buy rating on shares of Gray Television in a research note on Thursday, May 9th. Northland Securities restated a buy rating and issued a $55.00 price objective on shares of Heron Therapeutics in a research note on Thursday, May 9th. ValuEngine downgraded Verso from a hold rating to a sell rating in a research report on Thursday, May 23rd. Finally, Wells Fargo & Co reaffirmed a buy rating on shares of Flexion Therapeutics in a research report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $23.71.

FLXN opened at $10.65 on Tuesday. Flexion Therapeutics has a 52-week low of $9.65 and a 52-week high of $27.84. The company has a market capitalization of $414.09 million, a price-to-earnings ratio of -2.37 and a beta of 1.41. The company has a quick ratio of 6.06, a current ratio of 6.32 and a debt-to-equity ratio of 2.10. The stock’s 50-day moving average is $11.56.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.04. Flexion Therapeutics had a negative return on equity of 131.94% and a negative net margin of 549.07%. The business had revenue of $10.56 million for the quarter, compared to analyst estimates of $11.10 million. On average, equities research analysts anticipate that Flexion Therapeutics will post -4.07 earnings per share for the current year.

In related news, CFO David Arkowitz purchased 2,500 shares of Flexion Therapeutics stock in a transaction that occurred on Friday, May 31st. The shares were acquired at an average price of $11.05 per share, with a total value of $27,625.00. Following the completion of the transaction, the chief financial officer now directly owns 89,424 shares of the company’s stock, valued at approximately $988,135.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director C Ann Merrifield purchased 8,000 shares of Flexion Therapeutics stock in a transaction that occurred on Thursday, May 23rd. The shares were bought at an average cost of $12.64 per share, for a total transaction of $101,120.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $126,400. The disclosure for this purchase can be found here. Insiders have purchased 18,512 shares of company stock worth $226,775 in the last three months. 16.01% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of FLXN. BNP Paribas Arbitrage SA boosted its holdings in shares of Flexion Therapeutics by 53,692.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 6,980 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of Flexion Therapeutics by 68.2% in the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 3,490 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Flexion Therapeutics by 341.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,455 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 8,084 shares in the last quarter. Royce & Associates LP acquired a new stake in shares of Flexion Therapeutics in the 1st quarter valued at $187,000. Finally, Redmile Group LLC boosted its holdings in shares of Flexion Therapeutics by 63.1% in the 1st quarter. Redmile Group LLC now owns 21,630 shares of the specialty pharmaceutical company’s stock valued at $270,000 after purchasing an additional 8,370 shares in the last quarter. 89.88% of the stock is currently owned by institutional investors and hedge funds.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Story: Understanding Stock Ratings

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.